-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 24, the official website of NMPA updated the information on the approved drugs, and the tranexamic acid injection of Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group passed the consistency evaluation
.
Tranexamic acid is one of the top 5 types of terminal hemostatic drugs in Chinese public medical institutions.
It has maintained a positive growth trend since 2016.
Currently, only tranexamic acid injection has been reviewed.
Yangzijiang has become the fourth company that has been reviewed
.
Figure 1: The latest approved products of Yangtze River Source: NMPA official website Figure 2: Sales of tranexamic acid in recent years (unit: ten thousand yuan) Source: Terminal competition pattern of public medical institutions in China Tranexamic acid currently on the market It mainly involves capsules, tablets and injections, with more than 100 approvals
.
According to the data of Minet.
com, in 2020, the sales of this variety in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 900 million yuan, and the growth rate in the first half of 2021.
up to 30%
.
Figure 3: Tranexamic acid has been reviewed earlier Source: Minet.
com consistency evaluation database Earlier, tranexamic acid injection has been approved by Ruiyang Pharmaceutical, Chengdu Lier Pharmaceutical, Shanxi Pude Pharmaceutical Sexual evaluation, Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group is the fourth
.
At present, the seventh batch of national procurement catalogues has been officially announced, and tranexamic acid injection may be listed in the next round of catalogues
.
Figure 4: TOP5 enterprise structure of tranexamic acid injection in 2021H1 Source: Terminal competition of public medical institutions in China After the review, the supplementary applications for the consistency evaluation of Chongqing Laimei Pharmaceutical, Hunan Dongting Pharmaceutical, and Guizhou Shengjitang Pharmaceutical are currently under review and approval
.
.
Tranexamic acid is one of the top 5 types of terminal hemostatic drugs in Chinese public medical institutions.
It has maintained a positive growth trend since 2016.
Currently, only tranexamic acid injection has been reviewed.
Yangzijiang has become the fourth company that has been reviewed
.
Figure 1: The latest approved products of Yangtze River Source: NMPA official website Figure 2: Sales of tranexamic acid in recent years (unit: ten thousand yuan) Source: Terminal competition pattern of public medical institutions in China Tranexamic acid currently on the market It mainly involves capsules, tablets and injections, with more than 100 approvals
.
According to the data of Minet.
com, in 2020, the sales of this variety in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 900 million yuan, and the growth rate in the first half of 2021.
up to 30%
.
Figure 3: Tranexamic acid has been reviewed earlier Source: Minet.
com consistency evaluation database Earlier, tranexamic acid injection has been approved by Ruiyang Pharmaceutical, Chengdu Lier Pharmaceutical, Shanxi Pude Pharmaceutical Sexual evaluation, Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group is the fourth
.
At present, the seventh batch of national procurement catalogues has been officially announced, and tranexamic acid injection may be listed in the next round of catalogues
.
Figure 4: TOP5 enterprise structure of tranexamic acid injection in 2021H1 Source: Terminal competition of public medical institutions in China After the review, the supplementary applications for the consistency evaluation of Chongqing Laimei Pharmaceutical, Hunan Dongting Pharmaceutical, and Guizhou Shengjitang Pharmaceutical are currently under review and approval
.
